Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols
| العنوان: | Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols |
|---|---|
| المؤلفون: | Michael Dördelmann, Martin Schrappe, Sally A. Coulthard, Martin Zimmermann, Michel Eichelbaum, Anja Möricke, A. Reiter, G Cario, André Schrauder, Peter Kaatsch, Martin Stanulla, Karl Welte, Hansjörg Riehm, Matthias Schwab, Elke Schaeffeler |
| المصدر: | Blood. 114:1314-1318 |
| بيانات النشر: | American Society of Hematology, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Male, Heterozygote, medicine.medical_specialty, Vincristine, Immunology, Biochemistry, Thiopurine S-Methyltransferase, Risk Factors, Germany, Internal medicine, Acute lymphocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, medicine, Asparaginase, Humans, Child, Childhood Acute Lymphoblastic Leukemia, Genetics, Hematology, Thiopurine methyltransferase, biology, Brain Neoplasms, business.industry, Daunorubicin, Homozygote, Infant, Cancer, Myeloid leukemia, Neoplasms, Second Primary, Methyltransferases, Cell Biology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Leukemia, Myeloid, Acute, Child, Preschool, biology.protein, Prednisone, Female, business, Follow-Up Studies, medicine.drug |
| الوصف: | Thiopurine methyltransferase (TPMT)is involved in the metabolism of thiopurines such as 6-mercaptopurine and 6-thioguanine. TPMT activity is significantly altered by genetics, and heterozygous and even more homozygous variant people reveal substiantially decreased TPMT activity. Treatment for childhood acute lymphoblastic leukemia (ALL) regularly includes the use of thiopurine drugs. Importantly, childhood ALL patients with low TPMT activity have been considered to be at increased risk of developing therapy-associated acute myeloid leukemia and brain tumors. In the present study, we genotyped 105 of 129 patients who developed a secondary malignant neoplasm after ALL treatment on 7 consecutive German Berlin-Frankfurt-Münster trials for all functionally relevant TPMT variants. Frequencies of TPMT variants were similarly distributed in secondary malignant neoplasm patients and the overall ALL patient population of 814 patients. Thus, TPMT does not play a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, according to Berlin-Frankfurt-Münster strategies. |
| تدمد: | 1528-0020 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45fa8227801ce7edaa3294860ca1b02aTest https://doi.org/10.1182/blood-2008-12-193250Test |
| رقم الانضمام: | edsair.doi.dedup.....45fa8227801ce7edaa3294860ca1b02a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|